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Abstract 
Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve advanced non-small 
cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients 
with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and 
platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 
expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, double 
immune checkpoint inhibition has shown promising results in treatment naïve patients with high tumor 
mutational burden (TMB). Of note, the presence of both negative PD-L1 expression and low TMB may 
identify a subgroup of patients who has little benefit from immunotherapy combinations and for whom the 
best treatment option may still be platinum-based chemotherapy. To date, first-line single agent immune 
checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of 
immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC 
patients. Finally, in EGFR mutated or ALK rearranged NSCLC, atezolizumab in combination with platinum-
based chemotherapy and bevacizumab is emerging as a potential treatment option upon progression to first 
line tyrosine kinase inhibitors.  
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Introduction 
The advent of immunotherapy has radically changed the therapeutic algorithm in non-small cell lung cancer 
(NSCLC).   
Immune checkpoint inhibitors (ICIs), by blocking inhibitory pathways that physiologically control the 
immune response, restore and sustain the immune system against cancer cells [1].   
In particular, the cytotoxic T-lymphocyte–associated-4 (CTLA-4) and the programmed cell death protein 1 
(PD-1) are receptors expressed on T cells that interacting with CD80/CD86 [2] and the programmed death-
ligand 1 or 2 (PD-L1 or PD-L2) [3], respectively, can promote and favor cancer cells immune evasion. 
Several ICIs, blocking the PD-1/PD-L1 and CTLA-4 inhibitory pathways, have been evaluated in NSCLC. 
Due to their better effectiveness and safety profile compared to chemotherapy, three of them, 
pembrolizumab, nivolumab (both anti PD-1 antibodies) and atezolizumab (anti PD-L1), are Food and Drug 
Administration approved monotherapy in NSCLC, pembrolizumab both as first and second line treatment, 
nivolumab and atezolizumab only in the second line setting. 
However, the treatment paradigm of NSCLC is quickly changing and interesting results from phase III trials 
evaluating first -line ICIs as either monotherapy or combination have been recently published. 
An open issue is how to choose the most correct therapeutic strategy and to properly select patients for the 
different available treatment options. In this review, we aimed to analyse and discuss the topic, highlighting 
the strengths and the critical aspects of the most recent trials, in order to help clinicians in their choice. In 
Table 1 and Figures 1-4 are summarized the main survival data from randomized trials comparing immune 
checkpoint inhibitors as monotherapy or in combination to standard first line chemotherapy in advanced 
NSCLC. 
 Single agent immunotherapy 
Pembrolizumab, a monoclonal antibody (mAb) directed against the PD-1 receptor, is the only approved 
immunotherapy as first line treatment in metastatic NSCLC. 
In the Keynote 001 trial, single-agent pembrolizumab showed a significant benefit in treatment naïve 
NSCLC patients, achieving a 58.3% of response rate (RR), a median progression free survival (PFS) of 12.5 
months and a 24-months overall survival (OS) rate of 60.6% in patients with a PD-L1 tumor proportion score 
(TPS) ≥ 50% [4]. 
According to these results together with the positive data as second line treatment in PD-L1 positive (TPS 
>1%) patients [5], pembrolizumab monotherapy was compared to first line platinum-based chemotherapy in 
treatment naïve advanced NSCLC patients, without EGFR mutation or ALK rearrangement and harboring a 
PD-L1 TPS ≥50% (Keynote 024) [6]. 
Patients were randomized to receive intravenous (iv) pembrolizumab 200 mg (flat dose) every 3 weeks or 
standard chemotherapy chosen according to the histology. PFS was the primary end point, OS, ORR, and 
safety were secondary end points. Crossover was allowed. 
At the primary analysis, pembrolizumab showed its superiority over chemotherapy with improvement in 
overall response rate (ORR= 44.8 vs 27.8%, p<0.001), median PFS (10.3 vs 6 months; HR 0.50; 95% CI: 
0.37–0.68; p < 0.001) (Table 1) and median OS (median not reached, HR 0.6, 95% CI: 0.41–0.89) (Table 1, 
Figure 1).  To note that 43.7% of patients in the chemotherapy arm switched to pembrolizumab at the time of 
disease progression so a significant OS advantage was probably hidden by crossover. Fewer grade 3 or 4 
treatment related adverse events were reported with pembrolizumab than chemotherapy (26.6% vs. 53.3%) 
and immune mediated adverse event were documented in 9.7% of patients in the pembrolizumab arm. 
Due to these promising data, on October 24 2016 U.S. FDA and on 15 December 2016 EMA, granted 
approval for pembrolizumab as first-line treatment in metastatic NSCLC with no EGFR or ALK alterations 
and high PD-L1 expression (TPS ≥50%). 
After a longer follow-up of 25 months, the updated HR for OS was 0.63 (95% CI: 0.47–0.86) and the median 
OS in the pembrolizumab arm 30 months (95% CI 18.3-NR) compared to 14.2 months (95% CI 9.8-19) in 
the chemotherapy arm (Table 1, Figure 1), despite a crossover rate of 62.3% [7]. In addition, PFS2, (the 
progression free survival after a second line treatment) was significantly better in the pembrolizumab arm 
with a difference in median PFS of about 10 months (18.3 vs 8.4 months, HR 0.54) [8]. 
Another anti-PD-1 inhibitor, nivolumab, was recently evaluated as first line treatment in advanced NSCLC, 
due to the survival benefit over standard second line chemotherapy documented in two distinct phase III 
trials [9,10].  
In a multicohort phase 1 Check-Mate 012, durable responses and favorable safety profile in NSCLC patients  
treated with first line nivolumab monotherapy were reported, with a RR of 50% and a median PFS of 10.6 
months in patients with PD-L1 expression level of 5% or higher [11].  
The phase III trial Checkmate 026 evaluated the effectiveness and safety of nivolumab versus standard 
doublet chemotherapy in stage IV NSCLC patients with >1% PD-L1 expression. Patient with EGFR or ALK 
driver alterations were excluded. The primary end point was PFS, as assessed by means of blinded 
independent central review (BICR), among patients with a PD-L1 expression level of 5% or more. 
Nivolumab was administered iv at the dose of 3 mg/kg every 2 weeks. At the time of disease progression 
crossover was allowed for patients in the chemotherapy arm. Among the predefined subgroup of 423 patients 
with PD-L1 >5%, nivolumab didn’t show an improvement in PFS as compared to chemotherapy (4.2 vs 5.9 
months; HR: 1.15; 95% CI: 0.91–1.45; p = 0.25) and median OS was similar between the two arms: 14.4 vs 
13.2 months (HR 1.02; 95% CI, 0.80 to 1.30) (Table 1, Figure 2). Toxicity profile was better with nivolumab 
than chemotherapy with 17.6% vs 50.6% of patients having grade 3-4 adverse events (AEs), respectively, 
and no new safety data emerged from this trial [12]. In a post-hoc analysis, nivolumab failed again to show a 
benefit over chemotherapy in patients with higher PD-L1 expression levels (PD-L1 TPS ≥50%) [12]. It is 
unknown why the two anti-PD-1 antibodies showed such different results in first line setting. Probably 
patient selection may be the primary cause, however potential pharmacologic differences between the two 
antibodies may also exist. Doubts on the PD-L1 tests (Dako 22C3 and Dako 28-8 for pembrolizumab and 
nivolumab, respectively), PD-L1 cut-off point (50% with pembrolizumab vs 5% with nivolumab) and PD-L1 
role as a biomarker emerged from this comparison [13]. In Checkmate 026, the subgroup of patients with 
PD-L1 expression ≥50%  was higher in the control arm compared to the nivolumab arm (74.1% vs 53.2%) 
[12]. In addition, a higher percentage of never smokers was included in Checkmate 026 (11%) [12] 
compared to Keynote 024 (3%) [6], suggesting a higher proportion of patients with low mutational load in 
the nivolumab trial. Finally, the turnaround time from patient selection to treatment, based on PD-L1 
expression, is not reported in Keynote 024 but is expected to be frequently longer than one month. There is a 
high probability that patients with relatively indolent disease were favored for inclusion in the Keynote 
study. Although Checkmate 026 trial failed to show a benefit for nivolumab as first line treatment in NSCLC 
patients with PD-L1≥ 5%, an exploratory analysis reported better results with nivolumab than chemotherapy 
among patients selected by high TMB in terms of RR (47% vs 28%) and median PFS (9.7 vs 5.8 months, HR 
0.62; 95% CI,0.38 to 1.00 ); OS did not show differences in the two groups probably due to the high 
crossover rate in the chemotherapy arm (68%).  Of note, patients treated with nivolumab characterized by 
both high TMB and high PD-L1 (≥50%) showed better RR than those with only one or neither of these 
marker (75% vs 32 % vs 16%, respectively). Patients with low- medium TMB showed better PFS with 
chemotherapy than nivolumab (6.9 vs 4.1 months; HR 1.82, 95% CI 1.30-2.55).  Intriguingly, if we consider 
patients with low/medium TMB but higher PD-L1 (≥ 50%), fewer than 10% were progression-free at 18 
months when treated with nivolumab [12]. However, this was not a pre-specified analysis so prospective 
trials are needed to validate these data. Currently, only patients with PD-L1 TPS ≥ 50% can receive 
immunotherapy (pembrolizumab) as first line treatment in clinical practice and they account for a maximum 
of 30% of all advanced NSCLC patients.  
To extend the use of immunotherapy to a larger population, recently Keynote 042 investigated the role of 
pembrolizumab versus chemotherapy as first line treatment in NSCLC patients with PD-L1 TPS ≥1% and no 
sensitizing EGFR mutations or ALK rearrangements [14]. Patients were randomized to receive iv 
pembrolizumab 200 mg every 3 weeks for up to 35 cycles or carboplatin combined to either paclitaxel or 
pemetrexed according to tumor histology for up to 6 cycles, pemetrexed maintenance was optional. The 
primary endpoint was OS sequentially tested in the pre-specified subgroups with PD-L1 TPS ≥50%, ≥20%, 
≥1%. PFS and RR in the same subgroups and safety in the whole population (TPS ≥1) were secondary 
endpoints. First line pembrolizumab significantly improved survival over platinum-based chemotherapy, 
with a median OS of 20.0 vs 12.2 months (HR 0.69, 95% CI 0.56-0.85), 17.7 vs 13.0 months (HR 0.77, 95% 
CI 0.64-0.92), 16.7 vs 12.1 months (HR 0.81, 95% CI 0.71-0.93) in patients with PD-L1 TPS ≥50%, ≥20%, 
≥1%, respectively (Table 1, Figures 1,2). An exploratory analysis showed an HR of 0.92, (95% CI 0.77-
1.11), in patients with PD-L1 TPS 1-49%. No advantages in PFS were reported, however, further follow-up 
is ongoing. Pembrolizumab safety profile was consistent with previous reports with a lower frequency of 
grade 3-4 treatment related adverse events than chemotherapy (17.8% vs 41%) despite longer exposure [14]. 
This was the first study using OS as primary endpoint that showed an advantage of immunotherapy over 
chemotherapy. The better toxicity profile may favor the use of pembrolizumab in NSCLC patients PD-L1 
positive but the real benefit is evident in the PD-L1 ≥50% subgroup so, at the moment, there will be no 
immediate change in clinical practice. Finally, a recent study addressed the question whether ICI 
monotherapy may be useful in EGFR mutated patients in first line setting. This phase II single arm trial 
tested pembrolizumab 200 mg iv every 3 weeks in EGFR mutated NSCLC patients with PD-L1 expression 
≥1%. The study was prematurely closed after 11 of 25 patients were treated. ORR was 0%, and concerns 
were raised about pneumonitis in patients exposed to EGFR tyrosine kinase inhibitors (TKIs) after 
progression to pembrolizumab [15].  
 
Immuotherapy plus chemotherapy 
With the same goal of extending immunotherapy to a larger population, the addiction of a PD-1/PD-L1 
inhibitor to standard chemotherapy has been investigated in NSCLC patients, regardless of PD-L1 
expression. Combining immunotherapy to cytotoxic agents may improve the immune system activity 
through the immunological effects of chemotherapy [16], such as the reduction of T-regulatory cells [17] and 
myeloid derived suppressor cells  activity [18], the increase of the cross-presentation of tumor antigens [19] 
and the induction of PD-L1 expression on tumor cells [20]. 
On May 10 2017, the U.S. Food and Drug Administration (FDA) approved pembrolizumab in combination 
with pemetrexed and carboplatin as first-line treatment in metastatic non-squamous NSCLC, irrespective of 
PD-L1 expression. This approval was based on the significant increase in ORR and PFS and the minimal 
worsening in toxicity profile reported in the cohort G of the phase II Keynote 021 [21]. In this cohort 123 
patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without EGFR mutations or ALK 
rearrangements were randomized to receive carboplatin plus pemetrexed with or without pembrolizumab as 
first-line therapy. The primary endpoint was ORR. Patients were stratified by PD-L1 TPS (<1% vs ≥1%). At 
the primary analysis, the association of pembrolizumab nearly doubled the ORR compared to chemotherapy 
alone (55% vs 29%, respectively; p=0.0016) and significantly improved median PFS (13.0 vs. 8.9 months; 
HR, 0.53; p = 0.0102). Similar OS was reported in the two arms (92 % at 6 months for both treatments; 75 % 
and 72 % at 1 year, for experimental and control arm respectively). In both group there were durable 
response with 29 out of 33 (88%) responders in the combination group and 14 out of 18 (78%) responders in 
the chemotherapy alone arm alive without progression at the time of data cutoff. There was a higher 
proportion of responses in patients with PD-L1 ≥50% but the sample was too small to define a sure 
relationship between PD-L1 expression levels and efficacy. The toxicity profile was as expected in both 
treatment groups [21]. Keynote 021 was the first published controlled trial to prospectively report a 
significant advantage with a manageable and predictable toxicity profile combing an ICI to standard 
chemotherapy (~40% of grade 3-4 treatment related adverse events). Nevertheless, in the absence of 
significant improvement in OS and of a phase III trial, this regimen was not widely adopted. In a subsequent 
analysis (median follow-up, 14.5 months), the HR for OS improved to 0.69 (95% CI, 0.36‒1.31) in favor of 
the combination arm [22]. At 23.9 months of follow up, higher ORR (56.7% versus 30%; p=0.0016) and PFS 
(HR, 0.53; 95% CI, 0.33‒0.89; p=0.0049) with median PFS of 24.0 months versus 9.3 months in favor of 
pembrolizumab-chemotherapy combination were reported. The HR for OS was further improved to 0.56 
(95% CI, 0.32‒0.95; p=0.0151) with a not reached median OS in the combination arm vs 21.1 months OS 
with chemotherapy alone [23] (Table 1, Figure 3) .   
The results of Keynote 189, a phase III placebo-controlled trial testing first line platinum-based 
chemotherapy with or without pembrolizumab in EGFR/ALK wild type non squamous NSCLC patients were 
recently published [24]. The trial design was perfectly superimposable to that of KEYNOTE021. OS and 
PFS, as assessed by blinded independent central radiologic review (BICR) were co-primary endpoints, 
stratification was based on PD-L1 TPS (negative or positive), among other factors. Crossover to 
pembrolizumab was allowed at progression. 
After a median follow-up of 10.5 months, the RR was 47.6% in the pembrolizumab-combo group vs 18.9% 
in the placebo-combo group (p<0.001) with a median duration of response of 11.2 and 7.8 months, 
respectively.  Patients treated with pembrolizumab plus chemotherapy showed 51% less likelihood to die 
compared to patients in the chemotherapy arm: median OS was not reached vs 11.3 months, respectively 
(HR 0.49; 95% CI, 0.38 to 0.64; P<0.001). Median PFS as 8.8 vs 4.9 months (HR 0.52; 95% CI, 0.43 to 
0.64; p<0.001) with and without pembrolizumab (Table 1, Figure 3). The greatest benefit of the addiction of 
pembrolizumab was evident among patients with PD-L1 TPS of 50% or higher. Nevertheless, all evaluated 
PD-L1 categories, including those with PD-L1 TPS inferior than 1% achieved advantage from 
pembrolizumab combination. 
Despite a crossover rate of about 50%, survival benefit was clearly maintained with pembrolizumab 
addiction, highlighting the superiority of the upfront combination therapy over a subsequent use of 
immunotherapy. As expected, neither an increase of adverse events which usually seem to be associated to 
chemotherapy nor a higher incidence of immune-mediated adverse events were reported. A significant 
increase in the rate of nephritis and acute kidney injury (5.2% vs. 0.5%) was the only exception, but it may 
be both a platinum-based chemotherapy toxicity and an immune mediated effect as reported in the past trials.  
Recently, the results of a twin phase III study, the Impower 132, assessing the efficacy and safety of 
atezolizumab in combination with platinum and pemetrexed chemotherapy compared to chemotherapy alone 
in non-squamous NSCLC without driver alterations, have been presented. Investigator assessed PFS and OS 
in the intention to treat (ITT) population were co-primary endpoints. Evaluable tissue was not mandatory for 
enrollment and it was available only for the 60% of patients. The study met its PFS co-primary endpoint with 
a median PFS of 7.6 months in the atezolizumab plus chemoterapy arm compared to 5.2 months with 
chemotherapy alone (HR 0.60, 95% CI: 0.49-0.72, p<0.0001) (Table 1, Figure 3). The PFS advantage was 
evident in all the key subgroups with better results in females, elderly patients, never smokers and patients 
without liver metastases. Interestingly, the PFS benefit was not significant in patients with liver metastases 
(HR 0.77 95% CI 0.47-1.25).  At an exploratory analysis that evaluated the PFS by PD-L1 status in 
biomarker evaluable patients, the benefit of adding atezolizumab was present in all the subgroups (PD-L1 
high, low or negative) with better results among patients with higher PD-L1 expression (Table 1, Figure 1). 
At this first interim analysis OS data was not mature yet, however it was numerically superior for the 
combination of atezolizumab and chemotherpy with a median OS of 18.1 months vs 13.6 months in the 
experimental vs control arm, respectively (HR 0.81; 95% CI 0.64-1.3, p=0.0797) (Table 1, Figure 3). OS will 
be further evaluated in the final analysis that is scheduled for 2019. Atezolizumab plus pemetrexed and 
carboplatin/cisplatin and pemetrexed showed a manageable safety profile, consistent with known toxicity 
profiles of single immunotherapy and chemotherapy, treatment related grade 3-4 adverse events were 
reported in 58% of patients [25]. Atezolizumab showed a survival benefit in combination with first line 
platinum-based chemotherapy also in the phase III trial Impower 130.  In this study 723 patients with stage 
IV non-squamous NSCLC were randomized to receive the combination of atezolizumab and carboplatin plus 
nab-paclitaxel (Arm A) vs the same chemotherapy alone (Arm B). In the Arm A, Atezolizumab was 
continued as maintenance treatment until loss of clinical benefit, while best supportive care or pemetrexed 
were planned as maintenance in Arm B. Patients with EGFR or ALK alterations were included in the ITT 
population only after progression to at least one previous targeted agent, overall 679 patients were EGFR 
wild type and ALK negative ITT population. The study met its two coprimary endpoints: PFS and OS. The 
combination treatment resulted in a statistically significant improvement in OS compared with chemotherapy 
alone with a median OS of 18.6 months vs 13.9 months, respectively (HR 0.79; 95% CI, 0.64-0.98; p = 
0.033) [26] (Table 1, Figure 3). At 12 months, 63.1% of patients in the combination group were alive 
compared with 55.5% in the control arm. Similarly, a significant improvement in PFS was reported with a 
median PFS of 7.0 months in Arm A vs 5.5 months in Arm B (HR 0.64; 95% CI, 0.54-0.77; p< 0.0001) 
(Table 1, Figure 3). The PFS and OS improvements occurred although only 20% of patients in the Arm B 
received pemetrexed as switch maintenance and despite the high cross over rate of 59%. PFS and OS benefit 
were evident in all PD-L1 subgroups and were consistent across all key subgroups, except in those patients 
with liver metastases or EGFR/ALK alterations. Grade 3/4 treatment-related adverse events occurred in 
73.2% vs 60.3% of patients in the combination vs the chemotherapy arm respectively.  
The addiction of immunotherapy to the combination of antiangiogenic agent and chemotherapy has also been 
investigated. The results of Impower150, a phase III study, combining atezolizumab to the standard first line 
therapy carboplatin, paclitaxel with or without bevacizumab, in chemo-naïve patients with stage IV non-
squamous NSCLC were recently published [27]. PFS in the ITT population with wild-type genotype (WT-
ITT population) and among WT ITT population with high expression of an effector T-cell (Teff) gene 
signature and OS in the ITT WT population were co-primary endpoints. The IMpower150 met its PFS and 
OS co-primary endpoints: the four drug combination showed an improvement in PFS in the ITT population  
(median PFS 8.3 vs. 6.8 months; HR 0.62; 95% CI, 0.52 to 0.74; P<0.001) (Table 1, Figure 3), in the ITT 
WT population with high Teff (median PFS 11.3 months vs 6.8 months; HR 0.51, 95% CI, 0.38 to 0.68; 
P<0.001) and also in the ITT population including patients with EGFR or ALK alterations, (median PFS 9.7 
months vs 6.1 months; HR 0.59, 95% CI, 0.37 to 0.94). Median OS among the patients in the ITT WT 
population was longer with the four-drug combination compared to the control arm (19.2 months vs. 14.7 
months; HR, 0.78; 95% CI, 0.64 to 0.96; P = 0.02) (Table 1, Figure 3).  The benefit was observed across all 
subgroups, irrespective of PD-L1 expression levels. Of note, the addiction of atezolizumab to bevacizumab 
plus chemotherapy showed a significant benefit in key subgroups with potential low benefit from ICI such as 
patients with EGFR/ALK alterations or with liver metastases (HR 0.54 for both subgroups) [27]. In the same 
analysis the addiction of atezolizumab to carboplatin and paclitaxel did not show a statistically significant 
OS benefit as respect to the standard combination, bevacizumab plus carboplatin and paclitaxel, but a trend 
towards an OS benefit was observed (19.4 vs 14.7 months, HR 0.88, 95% CI 0.72-1.08, p=0.20); data are not 
yet mature and will be tested again at the time of final analysis. Safety for the atezolizumab, bevacizumab 
and carboplatin-paclitaxel combination was consistent with the known safety profile of single agents, 
treatment related grade 3-4 adverse events were reported in 60% of patients. Overall, the four studies in non-
squamous NSCLC (Keynote 189, Impower 130, Impower 132, Impower 150), differ in several aspects: 
patients with EGFR or ALK rearrangements were excluded in the Keynote 189 and Impower 132, the 
percentage of PD-L1 negative patients was higher in the Impower 130 and 150 studies (~50%) compared to 
Keynote 189 (31%) and Impower 132 (23%), crossover was not allowed in Impower 150 while was 
permitted in Impower 130 (59%), Impower 132 (37%) and in Keynote 189 (41%), follow-up was longer in 
Impower150 compared to Keynote 189 (20 vs 10 months). If we indirectly compared Keynote 189 and 
Impower 150, the incremental effect of immunotherapy seems superior with pembrolizumab and pemetrexed 
combination compared to atezolizumab and chemotherapy (HR 0.68, 95% CI 0.48 – 0.95). The reasons of 
the great magnitude of the advantage with pembrolizumab and chemotherapy are unclear: less 
additive/synergistic effect of paclitaxel compared to pemetrexed, different impact of chemotherapy agents on 
the activity of immune checkpoint inhibitors [28], different antidrug-antibody level in response to 
pembrolizumab or atezolizumab [29], differences in the characteristics of two populations can be 
hypothesized. 
The association of immunotherapy and chemotherapy was also explored in squamous histology. 
The phase III trial Keynote 407 randomized stage IV untreated squamous NSCLC to receive carboplatin and 
paclitaxel or nab-paclitaxel plus pembrolizumab or placebo [30]. The primary endpoints were PFS by BICR 
and OS in the ITT. Patients were stratified according to PD-L1 expression (TPS ≤1% or ≥1%), choice of 
taxane (paclitaxel vs nab-paclitaxel), geographic region (East Asia vs rest of the world). Adding 
pembrolizumab to standard chemotherapy significantly improved OS over chemotherapy alone: median OS 
was 15.9 vs 11.3 months, respectively (HR 0.64, 95% CI 0.49-0.85, p=0.0008) (Table 1, Figure 3). The 
advantage was evident in all the subgroups regardless of PD-L1 expression levels even if with greater benefit 
in patients with higher PD-L1 TPS (HR 0.61 for TPS <1%, HR 0.57 for TPS 1-49%, HR 0.64 for TPS>50%) 
(Table 1). PFS was also improved with pembrolizumab with a median PFS of 6.4 vs 4.8 months (HR 0.56, 
95% CI 0.45-0.60) (Table 1, Figure 3) and the ORR was almost doubled (58.4% vs 35.0%, p=0.0004). 
Pembrolizumab plus chemotherapy showed again a tolerable safety profile and frequency and severity of 
toxicities were similar to chemotherapy alone (69.8% vs 68.2%) [30].  
Finally, Impower 131, showed a benefit of the combination of atezolizumab and chemotherapy as compared 
to chemotherapy alone in patients with stage IV squamous NSCLC, regardless of tumor PD-L1 expression 
level. 1,021 patients were randomly assigned to the combination of atezolizumab with carboplatin and 
paclitaxel (Arm A) or to atezolizumab plus carboplatin and nab-paclitaxel (Arm B) or to carboplatin and nab-
paclitaxel alone (Arm C) [31].  PFS and OS were co-primary endpoints. The outcomes of groups B and C 
were presented. The study met the PFS endpoint: median PFS was 6.3 vs 5.6 months in Arm B and Arm C 
respectively (HR 0.71, 95% CI 0.60-0.85, p=0.0001) (Table 1, Figure 3) with a reduced risk of disease 
progression or death in 29% of patients treated with atezolizumab combo compared to those receiving 
chemotherapy alone and a doubling of PFS benefit with immunotherapy combination: 12 months PFS rate 
was 24.7% in patients receiving immunotherapy vs 12% in those receiving chemotherapy alone. The benefit 
was consistent among all PD-L1 subgroups, including those with PD-L1–negative tumors and liver 
metastases, with better results in patients with higher PD-L1 levels. At this interim analysis no survival 
benefit was observed with the addition of atezolizumab: median OS was 14 months for atezolizumab plus 
chemotherapy vs 13.9 months for chemotherapy alone (Table 1, Figure 3). The rate of severe side effects was 
higher with the combined-modality treatment than with chemotherapy alone (69% vs 58%), but the safety 
profile was generally manageable and consistent with known toxicities of each agent. 
 
Immunotherapy combinations 
Several recent trials addressed the question whether combining different immunotherapies may improve 
outcomes in some patients. 
The phase I Checkmate 012 trial showed an improved efficacy of the combination of nivolumab and the anti-
CTLA4, ipilimumab, as respect to nivolumab monotherapy in all PD-L1 expression cohorts, with better 
results in those patients with higher PD-L1 levels. The adverse events were more frequent with the 
combination but still acceptable with 33% of treatment related grade 3-4 adverse event with the schedule 
nivolumab every 2 weeks (3 mg/Kg or 1 mg/Kg) and ipilimumab at 1 mg/kg every 6 weeks [32]. 
The phase III Checkmate 227 evaluated the efficacy of nivolumab monotherapy or nivolumab based 
combinations (nivolumab plus chemotherapy or nivolumab plus ipilimumab) as first line therapy in chemo-
naive stage IV or recurrent NSCLC patients, randomized according to PD-L1 expression levels (>1% or 
<1%). The study was emended ongoing and two co-primary end points were established: PFS (assessed by 
BICR) with nivolumab plus ipilimumab versus chemotherapy in a TMB selected population and OS with 
nivolumab plus ipilimumab versus chemotherapy in a PD-L1 selected population [33]. 
Overall, RR and PFS were significantly improved with nivolumab plus ipilimumab compared to 
chemotherapy among patients with a high TMB (≥10 mutations per megabase) regardless of PD-L1 levels: 
RR was 45.3% vs 26.9% and median PFS 7.2 vs 5.5 months (HR 0.58; 97.5% CI, 0.41 to 0.81; P<0.001) 
(Table 1, Figure 3), with 43% vs 13% of patients being progression-free at 1 year. A subgroup analysis 
among patients with a high TMB showed longer PFS with nivolumab plus ipilimumab among both patients 
with a PD-L1 expression level of at least 1% and those with a level of less than 1% irrespective of histology 
(squamous vs non-squamous). At the same analysis the nivolumab plus ipilimumab combination showed 
better results than nivolumab monotherapy in patients with high TMB, underlining the positive impact of a 
dual immune checkpoint blockade in this subset of patients. The safety of nivolumab plus ipilimumab were 
consistent with Checkmate 012 trial and grade 3-4 adverse event were reported in 31.2% of patients treated 
with nivolumab plus ipilimumab. An exploratory analysis on the efficacy and safety of nivolumab plus 
ipilimumab and nivolumab plus chemotherapy vs chemotherapy alone in patients with <1% PD-L1 
expression were recently presented. PFS in nivolumab plus chemotherapy vs chemotherapy alone in patients 
with <1% PD-L1 expression level was one of the secondary endpoints [34]. The chemo-immunotherapy 
combination showed a significant benefit compared to chemotherapy alone: longer median PFS 5.6 vs 4.7 
(HR 0.74, 95% CI 0.58-0.94), higher ORR (36.7 vs 23.1) and longer duration of responses (7.2 vs 4.7 
months) (Table 1, Figure 4). The PFS benefit was enhanced according to TMB and patients with low TMB 
(<10mut/Mb) did not show any advantage by the combination of nivolumab either with chemotherapy or 
ipilimumab. Nivolumab plus ipilimumab showed higher PFS (1-year PFS rates: 45% vs 27% vs 8%) and 
more durable responses (1-year DOR 93% vs 33% vs not-calculated) in patients with high TMB and <1% 
PD-L1 expression level as compared to nivolumab plus chemotherapy and chemotherapy alone. Of note, no 
clear benefit was evident with combination strategies (nivolumab plus ipilimumab or chemotherapy) in those 
patients with <1% PD-L1 expression level and TMB <10 mut/Mb. 
More recently, in an unpublished updated exploratory analysis the combination nivolumab plus ipilimumab 
showed a HR for OS of 0.77 (95% CI: 0.56 to 1.06) compared to chemotherapy in patients with TMB ≥10 
mut/Mb , similarly to what observed in patients with TMB <10 mut/Mb (HR 0.78; 95% CI: 0.61 to 1.00) 
[35]. The median OS in patients with TMB ≥10 mut/Mb was 23.0 months in the combination arm vs 16.7 
months in the chemotherapy arm; the same difference was evident also in patients with TMB <10 mut/Mb: 
median OS 16.2 months vs 12.4 months in the combination and chemotherapy arms, respectively (Table 1, 
Figure 3). 
Double immune checkpoint blockade was also tested in the MYSTIC trial, a phase III study comparing 
durvalumab monotherapy or durvalumab and tremelimumab vs platinum-based chemotherapy in treatment 
naive metastatic NSCLC. A press release recently reported that MYSTIC did not meet the primary endpoint 
of improving PFS compared to standard therapy in patients with PD-L1 TPS ≥ 25% [36]. 
 
PD-1/PD-L1 inhibitors plus target therapy  
The role of ICIs in oncogene-addicted NSCLC is still unclear.  Currently, TKIs represent the standard 
treatment in patients with NSCLC associated with EGFR mutations or ALK and ROS1 rearrangements. 
Target therapy can cause the release of new antigen able to boost the immune response [37], from here the 
idea of combining immunotherapy to target therapy to improve clinical outcomes. To date, toxicities issues 
have hampered the development of combinations of ICIs and of EGFR or ALK TKIs. The phase Ib TATTON 
study testing osimertinib and nivolumab was early closed due to the occurrence of interstitial lung disease in 
38% of patients [38]. Due to this safety concerns, the recruitment in the CAURAL phase III trial evaluating 
the combination of osimertinib and durvalumab vs osimertinib alone in EGFR T790M positive patients after 
failure of a previous EGFR TKI was prematurely stopped.  
The combination of nivolumab and erlotinib showed grade 3-4 toxicities rate of 25% and an ORR of 15% in 
21 EGFR mutant NSCLC (20 pretreated with an EGFR TKI) [39]. Similar safety results were reported in 
EGFR TKI naïve patients with the combination of erlotinib and atezolizumab (grade 3-4 toxicities 39%) [40] 
or gefitninb and durvalumab (grade 3-4 toxicities 20%) [41], in both studies the ORR was ~75%, apparently 
comparable to the ORR with single agent EGFR TKI in this setting. In ALK rearranged NSCL patients, the 
phase I/II CheckMate 370 showed severe hepatic toxicities in 38% of patients treated with nivolumab and 
crizotinib [42]. However, the combination of alectinib and atezolizumab had an acceptable safety profile and 
the main grade 3-4 toxicity was skin rash, reported in 18.9% of patients [43]. Due to the high incidence of 
high-grade toxicities with combination of TKI and immunotherapy, further development of this approach 
remains controversial and should be investigational. 
 
Perspective and patients’ selection 
Although immunotherapy has widely changed the treatment paradigm in NSCLC, the best first line therapy 
in advanced NSCLC patients is still a matter of debate. 
To date, PD-L1 expression by immunohistochemistry (IHC) is the only approved marker to select patients 
for immunotherapy but its role as biomarker is not yet completely clear. 
To define the PD-L1 expression level, companies used distinct PD-L1 IHC assays (Dako 28-8, Dako 22C3, 
Ventana SP142, Ventana SP263 assay for nivolumab, pembrolizumab, atezolizumab and durvalumab, 
respectively) such as different methods of interpretation and cut offs. Despite patients with higher PD-L1 
expression level show higher likelihood of response to ICIs, about 10% of patients with negative PD-L1 
respond to anti PD1/PD-L1 ICIs as well as some PD-L1 highly positive patients do not respond [5, 9, 10, 34, 
35]. Intratumoral heterogeneity, interobserver variability, technological limits and dynamic nature of the PD-
L1 may also be the reason of absence of concordance between responses and the reported PD-L1 value. 
Moreover, biopsy is often not representative of the tumoral PD-L1 real expression [44]. 
PD-L1 on its own may not be informative enough for the correct selection of patients. According to the PFS 
results of Checkmate 026 [12] and 227 [32], TMB was considered as a potential new and independent 
biomarker and the nivolumab plus ipilimumab combination could represent the treatment of choice for high 
TMB patients, irrespective of PD-L1 expression level. Furthermore, considering the reported advantage in 
patients with higher TMB (≥10 mut/Mb), TMB testing may be also clinically useful to select patients for the 
chemotherapy plus immunotherapy combinations. Those patients with low TMB (<10 mut/Mb), that did not 
show any benefit from nivolumab combination neither with chemotherapy or ipilimumab, may be excluded 
from both these combinations. Nevertheless, both TMB feasibility and predictive value remains highly 
questionable. Regarding TMB feasibility, in Checkmate 227, only 57.7% of the collected samples were 
adequate for TMB analysis, and TMB positive patients were only 10.3% and 17.1% of the screened and 
enrolled patients respectively [32]. Recently blood TMB upon atezolizumab treatment was evaluated in 
pretreated NSCLC patients from OAK and POPLAR studies[45] and in treatment naïve NSCLC patients 
from the single arm phase II study B-F1RST [46]. In booth settings, blood TMB was feasible in 75%-78% of 
patients and the rate of positive TMB (≥10 mutations per megabase) ranged between 23% and 30%, 
suggesting that TMB may be more easily tested on blood rather than on tumor biopsies. Recent evidence 
from LACE-BIO II study including 908 resected stage II-III NSCLC patients showed a better OS and 
disease-free survival in patients with TMB >8 Mb, suggesting a prognostic rather than a predictive value for 
this biomarker [47]. Furthermore, although TMB on tissue (cut off 10 mutations per megabases) or blood 
(cut off 16 mutations per megabases) significantly correlated with a PFS benefit upon nivolumab in 
Checkmate 026 [12] and atezolizumab in the pooled analysis of OAK and POPLAR studies [45], absence of 
significant association between blood TMB and PFS upon atezolizumab was observed in the B-F1RST study 
[46] and the press release regarding OS from Checkmate 227 [35] questioned the predictive role of TMB 
from tissue for nivolumab and ipilimumab combination. Overall, as PD-L1, TMB is a dynamic biomarker 
and it may change over the time; intra-tumoral heterogeneity may condition NGS results; an accepted 
definition such as a universally defined cut-point to determine “high” TMB is currently lacking, there is not 
sufficient ability to reproduce results using different platforms/assays, and finally costs are not well 
established and biopsy specimens are not often big enough to obtain good quality DNA for assessment [48].  
A better characterization of patients with poor outcome during first line immunotherapy remains an unmet 
need. Both in patients treated with nivolumab single agent (Checkmate 026) or in combination with ipili-
mumab (Checkmate 227), the progression rate is higher in the immunotherapy arm (27% vs 10% in Check-
Mate 026 and 15.8% vs 11.9% in Checkmate 227) [12,32]. Furthermore, the crossings of the Kaplan Meier 
curves both in studies with single agent immune checkpoint inhibitors in first (Keynote 042 [14] and 
Checkmate 026 [12]) or further lines (Checkmate 057 [10])  or with double immune checkpoint combination 
(Checkmate 227 [32]) suggests that a variable percentage of NSCLC patients (ranging from 14% [49] to 
26% [50]) may have a clear worse prognosis when treated with immunotherapy compared to chemotherapy. 
This could be due to hyperprogressive disease (HPD), an acceleration of tumor growth during immunothera-
py recently described in previously treated NSCLC patients and in several different cancer types [51] HPD 
could also explain the lower access to subsequent treatments in patients discontinuing single agent 
nivolumab (44% vs 64% in Checkmate 026) or nivolumab plus ipilimumab (34.4% vs 49.2% in Checkmate 
227) for reasons other than toxicities. Finally, a better characterization of the benefit of first-line ICI in chal-
lenging populations is of paramount. In this regard, steroids use (≥10 mg/die of prednisone-equivalent) was 
associated with worse outcome in NSCLC patients treated with anti-PD-1/PD-L1 agents [52]. Furthermore, 
in patients with EGFR/ALK alterations or with liver metastases the addition of atezolizumab to chemothera-
py doublet did not significantly improve survival [26], however, in these same populations the quadruple 
treatment with chemotherapy, bevacizumab and atezolizumab provided a clear benefit [27], suggesting a po-
tential role of antiangiogenetic drugs in these settings. The benefit of single agent immunotherapy in elderly 
patients is still a matter of debate [53], and a subgroup analysis from Impower 132 raised the same question 
for immunotherapy and chemotherapy combinations due to the absence of significant OS benefit in patients 
older than 65 years treated with atezolizumab and platinum-pemetrexed [54]. It’s likely that immunosenes-
cence, a measure of the immunological age might play a more relevant role rather than chronological age it-
self to select patients who do not benefit from immune checkpoint blockade [55,56].      
Recent data reported that intestinal microbiota may influence the antitumor activity of immunotherapy: the 
intestinal bacterial flora would be able to regulate the activation of immune cells and so the global activity of 
immunotherapy [57–60]. Interestingly NSCLC patients treated with antibiotics within 30 days from the be-
ginning of ICI had shorter PFS (1.9 vs 3.8 months, HR 1.5, p=0.03) compared to patients who did not receive 
any antibiotics [61]. Furthermore, in one recent study including 100 cancer patients (60 NSCLC) Akkerman-
sia muciniphila was significantly enriched in responders compared to progressing patients (69% vs 34% 
p=0.007) and correlated with enhanced Th-1 cytokine (i.e. IL-12) production and increased intratumoral 
CD4/Foxp3 ratio [57]. These data suggest that the negative impact of antibiotics on patients’ outcome upon 
immune checkpoint blockade are likely related to the modification of the intestinal microbiota. 
Finally, a review and metanalysis of 20 randomized controlled trials of ICIs (including NSCLC trials), 
showed that the magnitude of OS benefit with ICIs may be sex-dependent, favoring men respect to women 
with a statistically significant difference (p=0.0019). According with this result sex should be taken into 
account in the evaluation risk vs benefit and different approaches may be explored in women or men [62].  
Researcher who are involved in clinical trials should develop original and high-quality study designs, such as 
adaptive or basket biomarker enriched clinical trials, included in large collaborative platforms with multiple 
active sites and cross-sector collaboration, to better clarify the role and the impact of different factors in the 
effectiveness of immunotherapy [63]. Together with the identification of new biomarkers, it may help 
clinicians to personalize immunotherapies and maximize patient’s outcomes.  
Conclusions 
In conclusion, immune checkpoint blockade has broadly revolutionized the first line treatment of advanced 
NSCLC patients with no oncogenic drivers. While the combination of anti-PD1/PD-L1 agents and 
chemotherapy was associated with significant benefit regardless of PD-L1 expression, first-line single-agent 
immunotherapy prolonged survival only in high PD-L1 selected patients. TMB is emerging as a novel 
marker, and non-invasive measurement of bTMB could represent a future more feasible tool. To date, TMB 
positive patients are the best candidate for double immune checkpoint blockade, while platinum-based 
chemotherapy may represent still the only first line option for patients with no PD-L1 expression and low 
TMB. Nevertheless, the predictive value of TMB should be further investigated in future randomized trials.  
In EGFR mutated NSCLC no activity signals were reported with single-agent pembrolizumab in an early 
study, however, the combination of first-line chemo-bevacizumab plus immunotherapy produced positive 
results in oncogene addicted NSCLC patients progressing to previous tyrosine kinase inhibitors. The addition 
of antiagiogenetics may be also a promising option for patients with liver metastases who seem to have a 
worse survival outcome upon immunotherapy and chemotherapy combinations. The validation of PD-L1 
expression, TMB and other biomarkers in order to identify patients who can mostly benefit from ICIs, the 
characterization of hyperprogressive disease and of the mechanistic bases explaining the negative impact of 
corticosteroids, antibiotics use, immunological aging and female sex on patients’ outcome upon ICIs 
represent the tough challenges for future research in this field of cancer treatment.   
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Table 1. Survival results from randomized trials exploring PD-(L)-1 inhibitors as monotherapy or in combi-
nation with anti-CTLA-4 agents or with standard first line chemotherapy in advanced NSCLC patients 
 
Figure 1. Survival results from randomized trials exploring PD-(L)-1 inhibitors in “high” PD-L1 NSCLC pa-
tients   
 
Figure 2. Survival results from randomized trials exploring PD-(L)-1 inhibitors in “positive” PD-L1 NSCLC 
patients   
 
Figure 3. Survival results from randomized trials exploring PD-(L)-1 inhibitors in NSCLC patients unselect-
ed for PD-L1 expression   
 
Figure 4. Survival results from randomized trials exploring PD-(L)-1 inhibitors in “negative” PD-L1 
NSCLC patients   
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